March 30, 2020 -- Generation Bio and Vir Biotechnology have agreed to collaborate on research into the use of monoclonal antibodies against the SARS-CoV-2 virus that causes COVID-19.
The collaboration will allow Generation Bio's gene therapy platform, which delivers genetic information to cells without the use of adeno-associated viruses, to be combined with Vir's neutralizing antibodies, the two firms said.
Vir's leading antibody was developed from a patient who recovered from SARS-CoV-1 and could neutralize SARS-CoV-2, according to Generation Bio and Vir.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: